133 related articles for article (PubMed ID: 20809117)
1. Expression patterns of microRNAs are altered in hypoxic human neuroblastoma cells.
Yamagata T; Yoshizawa J; Ohashi S; Yanaga K; Ohki T
Pediatr Surg Int; 2010 Dec; 26(12):1179-84. PubMed ID: 20809117
[TBL] [Abstract][Full Text] [Related]
2. Tumour-suppressor microRNAs let-7 and mir-101 target the proto-oncogene MYCN and inhibit cell proliferation in MYCN-amplified neuroblastoma.
Buechner J; Tømte E; Haug BH; Henriksen JR; Løkke C; Flægstad T; Einvik C
Br J Cancer; 2011 Jul; 105(2):296-303. PubMed ID: 21654684
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of mir-21, which is up-regulated during MYCN knockdown-mediated differentiation, does not prevent differentiation of neuroblastoma cells.
Buechner J; Henriksen JR; Haug BH; Tømte E; Flaegstad T; Einvik C
Differentiation; 2011 Jan; 81(1):25-34. PubMed ID: 20980091
[TBL] [Abstract][Full Text] [Related]
4. Focal DNA copy number changes in neuroblastoma target MYCN regulated genes.
Kumps C; Fieuw A; Mestdagh P; Menten B; Lefever S; Pattyn F; De Brouwer S; Sante T; Schulte JH; Schramm A; Van Roy N; Van Maerken T; Noguera R; Combaret V; Devalck C; Westermann F; Laureys G; Eggert A; Vandesompele J; De Preter K; Speleman F
PLoS One; 2013; 8(1):e52321. PubMed ID: 23308108
[TBL] [Abstract][Full Text] [Related]
5. MYCN-regulated microRNAs repress estrogen receptor-alpha (ESR1) expression and neuronal differentiation in human neuroblastoma.
Lovén J; Zinin N; Wahlström T; Müller I; Brodin P; Fredlund E; Ribacke U; Pivarcsi A; Påhlman S; Henriksson M
Proc Natl Acad Sci U S A; 2010 Jan; 107(4):1553-8. PubMed ID: 20080637
[TBL] [Abstract][Full Text] [Related]
6. MYCN regulates oncogenic MicroRNAs in neuroblastoma.
Schulte JH; Horn S; Otto T; Samans B; Heukamp LC; Eilers UC; Krause M; Astrahantseff K; Klein-Hitpass L; Buettner R; Schramm A; Christiansen H; Eilers M; Eggert A; Berwanger B
Int J Cancer; 2008 Feb; 122(3):699-704. PubMed ID: 17943719
[TBL] [Abstract][Full Text] [Related]
7. MicroRNA-184 inhibits neuroblastoma cell survival through targeting the serine/threonine kinase AKT2.
Foley NH; Bray IM; Tivnan A; Bryan K; Murphy DM; Buckley PG; Ryan J; O'Meara A; O'Sullivan M; Stallings RL
Mol Cancer; 2010 Apr; 9():83. PubMed ID: 20409325
[TBL] [Abstract][Full Text] [Related]
8. Biological effects of induced MYCN hyper-expression in MYCN-amplified neuroblastomas.
Torres J; Regan PL; Edo R; Leonhardt P; Jeng EI; Rappaport EF; Ikegaki N; Tang XX
Int J Oncol; 2010 Oct; 37(4):983-91. PubMed ID: 20811720
[TBL] [Abstract][Full Text] [Related]
9. Widespread dysregulation of MiRNAs by MYCN amplification and chromosomal imbalances in neuroblastoma: association of miRNA expression with survival.
Bray I; Bryan K; Prenter S; Buckley PG; Foley NH; Murphy DM; Alcock L; Mestdagh P; Vandesompele J; Speleman F; London WB; McGrady PW; Higgins DG; O'Meara A; O'Sullivan M; Stallings RL
PLoS One; 2009 Nov; 4(11):e7850. PubMed ID: 19924232
[TBL] [Abstract][Full Text] [Related]
10. miRNA expression profiling of the murine TH-MYCN neuroblastoma model reveals similarities with human tumors and identifies novel candidate miRNAs.
Terrile M; Bryan K; Vaughan L; Hallsworth A; Webber H; Chesler L; Stallings RL
PLoS One; 2011; 6(12):e28356. PubMed ID: 22164278
[TBL] [Abstract][Full Text] [Related]
11. Exosome-like Extracellular Vesicles from MYCN-amplified Neuroblastoma Cells Contain Oncogenic miRNAs.
Haug BH; Hald ØH; Utnes P; Roth SA; Løkke C; Flægstad T; Einvik C
Anticancer Res; 2015 May; 35(5):2521-30. PubMed ID: 25964525
[TBL] [Abstract][Full Text] [Related]
12. Deep MicroRNA sequencing reveals downregulation of miR-29a in neuroblastoma central nervous system metastasis.
Cheung IY; Farazi TA; Ostrovnaya I; Xu H; Tran H; Mihailovic A; Tuschl T; Cheung NK
Genes Chromosomes Cancer; 2014 Oct; 53(10):803-14. PubMed ID: 24898736
[TBL] [Abstract][Full Text] [Related]
13. MYCN-regulated miRNA-92 inhibits secretion of the tumor suppressor DICKKOPF-3 (DKK3) in neuroblastoma.
Haug BH; Henriksen JR; Buechner J; Geerts D; Tømte E; Kogner P; Martinsson T; Flægstad T; Sveinbjørnsson B; Einvik C
Carcinogenesis; 2011 Jul; 32(7):1005-12. PubMed ID: 21572098
[TBL] [Abstract][Full Text] [Related]
14. A genome-wide search for promoters that respond to increased MYCN reveals both new oncogenic and tumor suppressor microRNAs associated with aggressive neuroblastoma.
Shohet JM; Ghosh R; Coarfa C; Ludwig A; Benham AL; Chen Z; Patterson DM; Barbieri E; Mestdagh P; Sikorski DN; Milosavljevic A; Kim ES; Gunaratne PH
Cancer Res; 2011 Jun; 71(11):3841-51. PubMed ID: 21498633
[TBL] [Abstract][Full Text] [Related]
15. Differential patterns of microRNA expression in neuroblastoma are correlated with prognosis, differentiation, and apoptosis.
Chen Y; Stallings RL
Cancer Res; 2007 Feb; 67(3):976-83. PubMed ID: 17283129
[TBL] [Abstract][Full Text] [Related]
16. Outcome of the p53-mediated DNA damage response in neuroblastoma is determined by morphological subtype and MYCN expression.
Carr-Wilkinson J; Griffiths R; Elston R; Gamble LD; Goranov B; Redfern CP; Lunec J; Tweddle DA
Cell Cycle; 2011 Nov; 10(21):3778-87. PubMed ID: 22052359
[TBL] [Abstract][Full Text] [Related]
17. ID2 expression in neuroblastoma does not correlate to MYCN levels and lacks prognostic value.
Vandesompele J; Edsjö A; De Preter K; Axelson H; Speleman F; Påhlman S
Oncogene; 2003 Jan; 22(3):456-60. PubMed ID: 12545167
[TBL] [Abstract][Full Text] [Related]
18. MYCN and HIF-1 directly regulate
Hains AE; Uppal S; Cao JZ; Salwen HR; Applebaum MA; Cohn SL; Godley LA
Epigenetics; 2022 Dec; 17(13):2056-2074. PubMed ID: 35942521
[TBL] [Abstract][Full Text] [Related]
19. Reciprocal antagonistic regulation of N-myc mRNA by miR‑17 and the neuronal-specific RNA-binding protein HuD.
Samaraweera L; Spengler BA; Ross RA
Oncol Rep; 2017 Jul; 38(1):545-550. PubMed ID: 28560387
[TBL] [Abstract][Full Text] [Related]
20. A combined gene expression and functional study reveals the crosstalk between N-Myc and differentiation-inducing microRNAs in neuroblastoma cells.
Zhao Z; Ma X; Shelton SD; Sung DC; Li M; Hernandez D; Zhang M; Losiewicz MD; Chen Y; Pertsemlidis A; Yu X; Liu Y; Du L
Oncotarget; 2016 Nov; 7(48):79372-79387. PubMed ID: 27764804
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]